Medimpact

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

ETHACRYNIC ACID

| Generic | Brand | HICL | GCN | Medi-Span | Exception/Other |
|-----------------|-----------------|-------|-----|--------------|-----------------|
| ETHACRYNIC ACID | EDECRIN, | 03659 | | GPI-10 | |
| | ETHACRYNIC ACID | | | (3720002000) | |

GUIDELINES FOR USE

- 1. Does the patient have **ONE** of the following diagnoses?
 - Edema associated with congestive heart failure, cirrhosis of the liver, or renal disease (including nephrotic syndrome)
 - Ascites due to malignancy, idiopathic edema, or lymphedema

If yes, continue to #2. If no, do not approve. **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have a trial of or contraindication to **TWO** generic loop diuretics (e.g., furosemide, bumetanide, torsemide)?

If yes, approve for 12 months by HICL or GPI-10. If no, do not approve. DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ETHACRYNIC ACID (Edecrin)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Edema (swelling caused by fluid build-up in the body) associated with congestive heart failure (a type of heart condition), cirrhosis (liver damage), or renal disease (including nephrotic syndrome [a type of kidney disorder])
 - 2. Ascites (accumulation of fluid in the abdominal cavity) due to malignancy (cancer), idiopathic (unknown cause) edema, or lymphedema (swelling in an arm or leg due to build-up of lymph fluid)
- B. You had a trial of or contraindication (harmful for) to TWO generic loop diuretics (such as furosemide, bumetanide, torsemide)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE

Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Medimpact

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

ETHACRYNIC ACID

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Edecrin.

REFERENCES

• Edecrin [Prescribing Information]. Greenville, NC: Bausch Health Companies, Inc., August 2020.

| Library | Commercial | NSA |
|---------|------------|-----|
| Yes | Yes | No |

Part D Effective: N/A Commercial Effective: 07/01/22 Created: 05/22 Client Approval: 05/22

P&T Approval: 04/22

Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.